Novalis LifeSciences is a venture capital firm focused on early-stage investments in the life sciences industry, particularly at the intersection of bioinformatics and life sciences. Their strategy involves funding capital-light business models and platform technologies that apply innovative information technology to advance disease prevention, diagnosis, or treatment, across sectors like diagnostics, biopharma therapeutics, and life science tools.
67% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-b (44% of deals). Average disclosed round size is $63.1M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Flywheel | Series B | $27.5M | Dec 2025 |
 BlueWhale Bio, Inc. | Seed | $18M | Sep 2023 |
 Enko | Series C | $70M | Jul 2022 |
| VVizgen | Series C | $85.2M | Jun 2022 |
 Sherlock Biosciences | Series B | $80M | Mar 2022 |
 Ori Biotech Ltd | Series B | $100M | Jan 2022 |
 AgBiome LLC | Series D | $116M | Sep 2021 |
| VVizgen | Series B | $37M | Apr 2021 |
| AAllurion Technologies | Growth | $34M | Jan 2020 |
Top Co-Investors
Last updated: 16 April 2026